嘉正生物科技股份有限公司 Honeybear Biosciences, Inc.

HoneyBear Biotech is dedicated to developing antibody-related technology platforms and new drugs, with a particular focus on ADC research. Currently, they are actively advancing cutting-edge drug technologies that have the potential to overcome various limitations of existing therapies, addressing the growing need for effective cancer treatments in an aging society.

HoneyBear嘉正生物科技致力於抗體相關新技術平台及新藥開發，特別專注於抗體藥物複合體ADC研究。團隊於2022年技術移轉財團法人生物技術開發中心的 ”HBG2xP” 技術平台及ADC藥物，目前正積極開發先進藥物技術，有望克服現存藥物之多種缺陷，促進高齡化社會下日益增加的癌症患者有效治療。